Because the targeting of GREB1 Is4 could inhibit melanocytic melanoma growth in a different way from BRAF or immune checkpoint inhibitors, it paves the way for new clinical trials to eradicate malignant melanoma. This evidence concerns the gene GREB1 and melanoma.